Lawsuit claims supplement contained DMAA

A California class action lawsuit claims bodybuilding and weight management supplements from Florida-based BPI Sports contained undisclosed 1,3-dimethylamylamine (DMAA), an amphetamine-like ingredient that poses a serious health risk and has potentially life-threatening side effects, according to the suit.

As reported in Courthouse News, plaintiffs Clint Eskenski and Camden Brady allege BPI's best-selling products, "1.M.R" powder and tablets, "RoxyLean ECA" and "Rx6"' (marketed for bodybuilding and weight loss) contain the dangerous stimulant, which they were unaware of when they bought the products. The lawsuit says BPI failed to inform consumers of the DMAA content of its products, and accuses the company of selling synthetic DMAA even though it is marketed as an extract of geranium oil.

The plaintiffs seek restitution and class damages for consumer law violations, unfair competition, false and misleading advertising, breach of express warranty and breach of implied warranty.

DMAA is banned by several athletic organizations, including the World Anti-Doping Agency and Major League Baseball. It is illegal to sell in many countries, including Canada and New Zealand. The lawsuit says the ingredient is supposedly derived from the oil of the geranium plant. DMAA, also known as Methylhexanamine and Geranainine, is a vasoconstrictor and central nervous system stimulant.